Oral rinse

OTHER4 trials

Sponsors

Washington University School of Medicine, University Hospitals Cleveland Medical Center, University of Barcelona, ACTA Dental Research BV (ADR)

Conditions

Healthy VolunteersMantle Cell LymphomaPrevention & Controlhalitose (slechte adem) halitosis oral malodor

Phase 2

Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma

CompletedNCT03623373

Washington University School of MedicineMantle Cell Lymphoma

Start: 2018-11-29End: 2025-04-14Updated: 2026-03-30

Unknown Phase

The effect of glymur rinse on oral microbiological changes and changes in microbial activity related to halitosis

Active, not recruitingNL-OMON41897

ACTA Dental Research BV (ADR)halitose (slechte adem) halitosis oral malodor

Start: 2015-05-11Target: 20Updated: 2024-02-28

Human Skin and Gut Mycobiome and Bacteriome Comprehensive Registry

RecruitingNCT05196061

University Hospitals Cleveland Medical CenterHealthy Volunteers

Start: 2020-01-01End: 2030-12-31Target: 5000Updated: 2025-03-13

Substantivity of Oral Rinses: Comparative Study

CompletedNCT05365737

University of BarcelonaPrevention & Control

Start: 2022-01-01End: 2022-02-03Updated: 2022-05-11

Related Papers

A Pilot Study of Acalabrutinib with Bendamustine/Rituximab Followed By Cytarabine/Rituximab (R-ABC) for Untreated Mantle Cell Lymphoma

Blood2020-11-042 citations